Sign In
Buy IONS
$73.82
+0.85 (+1.16%)
At Close: Jun 03, 2026
Ionis Announces Proposed Convertible Offering to Refinance 2026 Convertible Notes
04:05pm, Tuesday, 11'th Nov 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it intends to offer, subject to market conditions and other factors, $700.0 million aggregate princip
Ionis Pharmaceuticals, Inc. (IONS) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia Transcript
04:31pm, Monday, 10'th Nov 2025
Ionis Pharmaceuticals, Inc. ( IONS ) Discusses Detailed Phase III Results for Olezarsen in Severe Hypertriglyceridemia November 8, 2025 3:00 PM EST Company Participants D. Walke - Senior Vice Presiden
Ionis: Near-Term Launches With Blockbuster Potential Boosts Upside Despite Stock Rally
03:31pm, Monday, 10'th Nov 2025
Ionis Pharmaceuticals maintains a Buy rating as its transformation to a commercial company accelerates, driven by wholly-owned product launches and revenue growth. Q3 results highlight a revenue shift
Ionis Reports Substantial Drop In Acute Pancreatitis Events With Cholesterol Lowering Drug
01:37pm, Monday, 10'th Nov 2025
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) on Sunday shared results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen for severe hypertriglyceridemia (sHTG), a condition characterized by dan
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with severe hypert
Ionis presents new data demonstrating long-term disease control with DAWNZERA™ (donidalorsen) at ACAAI 2025 Annual Meeting
08:00am, Thursday, 06'th Nov 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced new long-term data for DAWNZERA™ (donidalorsen), the first and only RNA-targeted prophylactic medicine f
Ionis: What Upside Is Left After Shares Rocketed Higher Following Positive Trial Data?
02:38pm, Tuesday, 04'th Nov 2025
Ionis Pharmaceuticals, Inc. has surged on strong phase-3 trial data and a robust pipeline, but much optimism is already priced in. IONS boasts recent drug launches (Wainua, Tryngolza, Dawnzera) with s
37,649 Shares in Ionis Pharmaceuticals, Inc. $IONS Bought by Y Intercept Hong Kong Ltd
03:39am, Monday, 03'rd Nov 2025
Y Intercept Hong Kong Ltd purchased a new position in shares of Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) in the undefined quarter, according to its most recent disclosure with the Securities and Exc
Ionis Beats Q3 Earnings & Sales Estimates, Raises 2025 Outlook
02:16pm, Thursday, 30'th Oct 2025
IONS' Q3 results top estimates as robust Tryngolza and Wainua sales drive revenue growth. The company raises its 2025 outlook for the third time this year.
Ionis Pharmaceuticals, Inc. (IONS) Q3 2025 Earnings Call Transcript
06:26pm, Wednesday, 29'th Oct 2025
Ionis Pharmaceuticals, Inc. ( IONS ) Q3 2025 Earnings Call October 29, 2025 11:30 AM EDT Company Participants D. Walke - Senior Vice President of Investor Relations Brett Monia - Founder, CEO & Direct
Compared to Estimates, Ionis Pharmaceuticals (IONS) Q3 Earnings: A Look at Key Metrics
10:31am, Wednesday, 29'th Oct 2025
Although the revenue and EPS for Ionis Pharmaceuticals (IONS) give a sense of how its business performed in the quarter ended September 2025, it might be worth considering how some key metrics compare
Ionis Pharmaceuticals (IONS) Reports Q3 Loss, Beats Revenue Estimates
09:16am, Wednesday, 29'th Oct 2025
Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $1.15. This compares to a loss of $0.95 per share a year ago.
Ionis reports third quarter 2025 financial results and highlights progress on key programs
07:00am, Wednesday, 29'th Oct 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results and provided key updates for the third quarter ended September 30, 20
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that detailed data from the landmark pivotal Phase 3 CORE and CORE2 studies of olezarsen in people with se
Ionis ranked #2 Top Employer by Science magazine, recognizing industry-leading scientific innovation and company culture
02:10pm, Thursday, 23'rd Oct 2025
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the company was named as a top employer to work for by Science magazine in its annual Top Employer survey
